2021 · New England Journal of Medicine
Dexamethasone in Hospitalized Patients with Covid-19
Verdict
UNSCIENTIFIC
The study follows the scientific method inside its paradigm. The paradigm itself does not pass. The verdict is unscientific.
1·Study methodology · inside the paradigm
SCIENTIFIC
Follows the scientific method within Allopathic Medicine. Shows how the conclusion was built; does not change the verdict.
2·Paradigm · Allopathic Medicine
UNSCIENTIFIC
Fails the tests. This decides the verdict.
How the verdict is decided
The verdict grades the whole picture: the paradigm this study assumes, and how the study was carried out inside it. A study can follow the scientific method rigorously and still be unscientific, because rigor inside a paradigm only shows the conclusion was reached carefully. It cannot verify the premise the paradigm rests on. So the paradigm decides the verdict. The study’s own score is kept because it shows how the conclusion was built.
1·Study methodology
Did this study test its claim with methods that are independent, falsifiable, and non-circular?
SCIENTIFIC
The drug dexamethasone reduces 28-day death in hospitalized patients diagnosed with what they call Covid-19. All three tests pass.
Independently Verifiable
Pass
A stranger who rejects the entire framework can still count whether a person died within 28 days of being assigned to a group.
Falsifiable
Pass
If the death count in the dexamethasone group had been equal to or higher than the usual care group, the claim that dexamethasone reduces mortality would have died.
Non-Circular
Pass
The instrument measuring the claim is arithmetic on a public outcome, not a probe built from a prior model.
Why
The study randomly assigned hospitalized patients to receive dexamethasone or usual care and counted deaths within 28 days. Death is an outcome a stranger can witness without joining any model. The arithmetic could have gone either direction, and a null or negative result would have killed the claim. The measurement instrument does not presuppose the conclusion. The patient cohort was sorted using model-dependent diagnosis, but the Layer Split rule places disease-category circularity on Layer 2, not Layer 1. The study is selling a survival difference between two assigned groups, and that difference was measured by counting bodies, not by running a probe. That is scientific methodology. The framework that produced the trial is a separate question.
2·Paradigm · Allopathic Medicine
Does the framework this study assumes pass the three tests?
UNSCIENTIFIC
Independently Verifiable
Fail
Every patient in the trial was sorted into the cohort by a diagnosis that required accepting the allopathic model first, so the population itself is a model-dependent artifact.
Falsifiable
Fail
If dexamethasone had failed, nobody would have concluded that the allopathic model of inflammation-mediated lung injury is wrong; they would have concluded this drug was suboptimal for this condition.
Non-Circular
Fail
The disease category was defined by tests built to find what the model already named, the drug targets a mechanism the model invented, and the survival difference is then cited as proof the model works.
Why
The allopathic model treats symptoms as the disease rather than as the body's response to underlying terrain damage. Dexamethasone suppresses inflammation, which the model calls the disease. The trial proves that suppressing inflammation keeps more people alive for 28 days. It does not prove the model understands why those people were sick, why their lungs were damaged, or what terrain conditions produced the damage in the first place. The patient cohort was defined by what they diagnosed as clinically suspected or laboratory-confirmed SARS-CoV-2 infection, a category produced by model-dependent tests. The drug targets a mechanism the model named. The outcome is counted as a win for the model. If the drug had failed, the model would have absorbed the failure as a dosing problem or a wrong drug, never as evidence the framework itself is wrong. That is an unfalsifiable loop. The study methodology is sound. The framework that generated it is not.
From the paper
Eligible patients were those who were hospitalized with clinically suspected or laboratory-confirmed SARS-CoV-2 infection.
The primary outcome was 28-day mortality.
Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization.
Source
Dexamethasone in Hospitalized Patients with Covid-19
Horby, P; Lim, WS; Emberson, JR; Mafham, M; Bell, JL; Landray, MJ
2021 · New England Journal of Medicine
Scored from full text · Rubric 1.0